Attractive interest rate: Investors receive 9.5% annual interest over a 4-year term, with quarterly interest payments - offering predictable and regular returns.
Proven technology: Proprietary robotics and precision dispensing platforms already trusted by more than 50 clients in 37 countries.
Recurring revenues: Around 25% of annual revenues come from long-term service contracts, spare parts, and software, providing stable cash flow.
Growing market: Strong exposure to fast-growing segments such as diagnostics, microfluidics (25% CAGR), and wearable health devices.
Global customer base: Over 150 automation systems delivered.
“Ginolis combines proven MedTech automation technology with a loyal global customer base and recurring revenues. With your support, we are now scaling into the DACH region, advancing our product line, and launching our Device-as-a-Service model. This funding accelerates our growth and strengthens our position as a leader in next-generation diagnostics automation. We invite you to join us in shaping the future of healthcare.”
Kauko Väinämö, CEO and R&D of Ginolis
Today, millions of people depend on fast and reliable medical tests. Yet producing these tests is still too slow and complex. Many companies rely on manual or semi-automated processes that cannot keep up with demand. For example, rapid COVID tests, blood glucose sensors for diabetes patients, or home fertility tests all require highly precise production. Without automation, scaling up these types of diagnostics and wearable health devices becomes expensive, error-prone, and too slow for global needs.
Ginolis solves this problem with smart automation. Using proprietary robotics, precision dispensing, and modular systems, Ginolis makes it easier and faster to manufacture advanced medical and diagnostic products. This allows healthcare companies to scale up production, reduce errors, and bring new innovations to patients quicker.
Founded in 2010 in Oulunsalo, Finland, Ginolis has already delivered more than 150 production lines to over 50 clients in 37 countries. Around a quarter of revenues now come from recurring service and maintenance contracts, creating stable income alongside new system sales and software solutions.
Following a management buyout in 2023, Ginolis has returned to profitable growth. With proven technology, a global customer base, and recurring revenues, the company is now expanding its microfluidics platform, scaling in the DACH region, and launching a Device-as-a-Service model.
When a new client starts working with Ginolis, the process is clear and structured:
Design phase: Ginolis engineers work with the client to understand their diagnostic product or wearable technology. Together, they design an automation solution tailored to the client’s needs.
Prototype and testing: A pilot setup is built and tested to ensure accuracy, reliability, and scalability. This step helps clients move smoothly from R&D into production.
Delivery and installation: The full automation line is manufactured with support from partners in Estonia and India. Ginolis installs the system at the client’s site and ensures everything runs seamlessly.
Service and support: After installation, Ginolis provides ongoing maintenance, spare parts, and upgrades. Dedicated service teams visit client sites, while software tools monitor performance and predict when maintenance is needed.
This approach creates long-term partnerships. Clients not only receive a production line but also continuous support that ensures reliable operation, reduced downtime, and lower costs over the system’s lifecycle.
| Company name: | Ginolis Oy |
|---|---|
| CEO: | Kauko Väinämö |
| Business ID number: | 2344452-8 |
| Founding year: | 2010 |
| Address: | Automaatiotie 1 90460 Oulunsalo Finland |
| Industry: | MedTech automation industry |
|---|---|
| Locations: | Finland & USA |
| Website: | ginolis.com |
| Social media: |
Medical technology is advancing fast, but scaling production is often the bottleneck. Ginolis removes this barrier. The company delivers smart automation systems that make the manufacturing of diagnostics and health technologies faster, more precise, and easier to scale. From rapid tests to microfluidics and wearable health devices, Ginolis’ solutions help innovators turn ideas into reliable products that can reach patients worldwide.
Automation platforms: Flexible systems that produce diagnostic devices like rapid tests. They include built-in quality control and can grow from small pilot runs to full-scale production.
Microfluidics solutions: The Kaste platform handles extremely small liquid samples with high precision - down to a fraction of a drop. This capability is crucial for next-generation healthcare, where just a tiny sample of blood, saliva, or sweat can deliver reliable results. With Kaste, companies can develop advanced tests for cancer detection, diabetes management, or stress-level monitoring, and scale them from research to full production.
Wearable device components: Ginolis develops modern manufacturing technologies for microsensors and components used in modern health wearables. These include technologies for continuous glucose monitoring, skin-based trackers, and other devices that measure vital signs. By automating production, Ginolis helps its clients bring reliable and affordable wearables to market faster.
Ginolis generates revenue by designing, delivering, and servicing automation systems for the medical technology and diagnostics industry. The model combines one-time sales of equipment with stable recurring revenues from services and software.
Equipment sales: Customers purchase automation platforms for diagnostics, microfluidics, or wearables. Contracts typically include staged payments - part at signing, part at delivery, and the remainder on agreed terms. This ensures cash flow throughout the project lifecycle.
Recurring revenues: About a quarter of annual revenues come from service and maintenance contracts, spare parts, and upgrades. These long-term partnerships provide stability and predictable income. Ginolis also provides software tools that monitor machine performance and predict when maintenance is needed, creating additional high-margin recurring revenues.
Customer segments: Ginolis serves leading pharmaceutical companies, diagnostic device makers, laboratories, and biosensor developers. The company has delivered more than 150 systems to over 50 clients in 37 countries.
Strategic growth: Expansion into the DACH region, growth in North America, and the planned Device-as-a-Service (DaaS) model will further strengthen recurring revenues and long-term customer relationships.
Strategic Partnerships
Alliances with industry leaders such as Stratec, Samuel Automation, TechGroup, and SARLA expand Ginolis’ market access and delivery capacity. These collaborations accelerate growth, provide local support, and allow Ginolis to focus its in-house resources on core technology and innovation.
Intellectual Property
Ginolis protects its innovations through multiple layers: patented dispensing and automation solutions, copyrighted software, and trademarked brands. This combination makes the business difficult to copy and creates high barriers to entry. Long product lifecycles of 7-10 years further strengthen customer lock-in and recurring revenue.
Ginolis is positioned in one of the most attractive growth areas of healthcare: MedTech automation. The demand for faster, more precise, and scalable diagnostic production is increasing worldwide.
Strong market growth:
• The global medical automation market is expected to nearly double from $48 billion in 2023 to $88 billion by 2030 (CAGR 9%).
• The microfluidics segment, where Ginolis’ Kaste platform is focused, is growing at 25% annually, one of the fastest-growing niches in healthcare.
• The laboratory automation market will expand from $6.9 billion in 2022 to $11.6 billion by 2030, offering long-term growth potential.
Clear demand drivers: Rapid testing, decentralized healthcare, and the boom in wearable devices and biosensors are fueling investment. Governments and healthcare providers are also accelerating adoption of local diagnostic capacity.
Competitive edge: While global players like Beckman Coulter and Tecan dominate mass automation, Ginolis offers something unique: compact, modular systems that combine flexibility with scalability. Proprietary dispensing technology, predictive maintenance software, and 150+ successful installations prove the company’s ability to compete and win.
High barriers to entry: Long sales cycles, client integration in regulated markets, and high switching costs create strong protection. Once installed, Ginolis systems remain in use for 7-10 years, ensuring stable service revenues and customer loyalty.
For investors, this means Ginolis is not only addressing large and growing markets but is also strategically positioned to capture market share with a proven, defensible business model.
The Sustainable Development Goals (SDGs or 'Global Goals') are part of the UN 2030 Agenda for Sustainable Development and constitute the international framework for sustainable development until 2030. These SDGs are intended to put an end to poverty, inequality, and climate change.
By automating the production of diagnostics and wearable health technologies, Ginolis helps make healthcare more accessible and reliable worldwide. The company’s solutions directly support the UN goal of improving global health and well-being.
SDG 3: Good Health & Well-being
Ginolis directly contributes to better healthcare by enabling faster, more accurate, and scalable production of diagnostic devices and wearable health technologies. Its automation systems help ensure that patients can access reliable tests from rapid point-of-care diagnostics to advanced microfluidics. By improving the availability and precision of these devices, Ginolis supports earlier diagnosis, more effective treatments, and ultimately healthier lives. With over 150 systems already installed worldwide, Ginolis’ technology is helping millions of people gain access to critical diagnostics each year.
CEO & R&D
Kauko is the CEO of Ginolis, bringing more than 25 years of experience in MedTech and automation. He has a strong background in mechanical engineering and has held leadership roles in high-tech companies. Under his guidance, the company has grown into a trusted partner for global diagnostics and pharma companies, delivering over 150 automation systems worldwide. After leading the management buyout from BICO in 2023, Kauko steered Ginolis back onto a profitable growth path. His expertise in microfluidics, robotics, and precision dispensing continues to shape the company’s innovative solutions and strengthen its leadership in diagnostic manufacturing.
General Manager, North America
Chris leads Ginolis’ operations in North America, one of the company’s key growth markets. He brings extensive experience in scaling international MedTech businesses and building customer relationships across the diagnostics and pharmaceutical sectors. His role is critical in executing Ginolis’ expansion strategy, especially as the company rolls out its Device-as-a-Service model and strengthens its market presence in the U.S. and Canada.
Ginolis Oy is the parent company and directly owned by its management team and life science investors. The company has one fully owned subsidiary in the United States, which supports sales and service activities in North America. In addition, Ginolis holds a number of dormant companies with no commercial activity.
Investors in this round are investing directly into Ginolis Oy, the Finnish operating company. Revenues and profits flow through this entity.
This straightforward structure ensures transparency for investors. With a clear line between the operating company and its subsidiary, Ginolis maintains full control over global activities while keeping legal and financial reporting simple.
Ginolis is raising up to €800,000 in debt financing through Invesdor. The proceeds will be used to accelerate growth and strengthen recurring revenues.
(funding of €100,000 - €300,000 collected in the financing round)
(funding of €300,000-€800,000 collected in the financing round)
These investments will allow Ginolis to expand its customer base, bring innovative products to market faster, and build a stronger recurring revenue stream. The goal is to become fully cash-flow positive by late 2025 and to reach approximately €19 million in revenue by 2029.
This section will be regularly updated with new, project-relevant information as the financing progresses. To be informed about new updates in a timely manner, subscribe to our newsletter.
You can reach us by mail, by phone and via our chat.
+358 40 779 5389
In our FAQ section you will find answers to frequently asked questions.
